12.2 Parkinson Disease: Clinical Presentation, Hoehn & Yahr Staging & Cueing

12.2 Parkinson Disease: Clinical Presentation, Hoehn & Yahr Staging & Cueing

[!NOTE] DHA Licensure Focus: Neurodegenerative movement disorders represent a major clinical pillar of the DHA Physiotherapist licensing examination. Candidates must understand the pathophysiological mechanisms governing basal ganglia circuitry, identify and differentiate the cardinal motor signs (TRAP: Tremor, Rigidity, Akinesia/Bradykinesia, Postural Instability), categorize disease severity along the Hoehn and Yahr scale, design evidence-based rehabilitation protocols utilizing external cueing and LSVT BIG paradigms, and coordinate therapy sessions around carbidopa/levodopa 'on-off' motor fluctuations.

Parkinson Disease (PD) is the second most common neurodegenerative disorder worldwide. It is characterized by progressive motor disability, postural decline, and non-motor complications that directly impact independence, safety, and quality of life.

---

1. Neuropathology and Basal Ganglia Circuitry

The central pathological hallmark of Parkinson Disease is the slow, progressive degeneration of pigmented dopaminergic neurons in the substantia nigra pars compacta (SNpc) located in the midbrain. By the time clinical motor signs manifest, approximately 60% to 80% of dopamine-producing cells in the SNpc have already been lost, alongside a 70% to 90% depletion of striatal dopamine concentrations.

+-----------------------------------------------------------------------------------+
|                    Basal Ganglia Pathway Neurochemistry in PD                     |
+-----------------------------------------------------------------------------------+
| CORTICAL MOTOR COMMANDS                                                           |
|        │                                                                          |
|        ▼                                                                          |
| STRIATUM (Caudate & Putamen) <─── [ LOSS OF DOPAMINE FROM SNpc ]                  |
|        │                                                                          |
|        ├────────────────────────────────────┬───────────────────────────────────┐ |
|        ▼                                    ▼                                   | |
| DIRECT PATHWAY (D1 Receptors):      INDIRECT PATHWAY (D2 Receptors):            | |
| Normal: Promotes Movement           Normal: Suppresses Movement                 | |
| In PD: UNDER-ACTIVATED              In PD: OVER-ACTIVATED                       | |
| (Decreased striatal inhibition      (Disinhibition of Subthalamic Nucleus [STN],| |
|  of GPi / SNpr)                      driving excessive excitation of GPi/SNpr)  | |
|        │                                    │                                   | |
|        └────────────────────────────────────┴───────────────────────────────────┘ |
|                                      │                                            |
|                                      ▼                                            |
|             INTERNAL GLOBUS PALLIDUS & SUBSTANTIA NIGRA RETICULATA                |
|                                 (GPi / SNpr)                                      |
|                       [ EXCESSIVE TONIC GABA INHIBITION ]                         |
|                                      │                                            |
|                                      ▼                                            |
|                        VENTROLATERAL MOTOR THALAMUS                               |
|                           [ PROFOUNDLY SUPPRESSED ]                               |
|                                      │                                            |
|                                      ▼                                            |
|                         CORTICAL MOTOR EXCITATION                                 |
|               [ POVERTY OF MOVEMENT: BRADYKINESIA & AKINESIA ]                    |
+-----------------------------------------------------------------------------------+

Lewy Bodies and Alpha-Synuclein Pathology

At the cellular level, surviving nigral neurons exhibit abnormal intracellular proteinaceous inclusions known as Lewy bodies. The primary structural constituent of Lewy bodies is misfolded, aggregated alpha-synuclein protein. According to the Braak staging hypothesis, Lewy pathology initiates caudally in the dorsal motor nucleus of the vagus nerve and olfactory bulbs (accounting for early non-motor symptoms such as constipation and anosmia) before ascending through the brainstem into the substantia nigra, and ultimately invading the cerebral cortex in advanced stages.

---

2. The Cardinal Motor Signs (TRAP)

The clinical diagnosis of Parkinson Disease requires the presence of bradykinesia combined with at least one of the following: muscular rigidity, resting tremor, or postural instability.

+-----------------------------------------------------------------------------------+
|                    The Cardinal Motor Tetrad (TRAP) of PD                         |
+-----------------------------------------------------------------------------------+
| T - Tremor: Resting tremor at 4-6 Hz ('pill-rolling'); asymmetric onset;          |
|             suppressed during voluntary movement and sleep; exacerbated by stress |
+-----------------------------------------------------------------------------------+
| R - Rigidity: Lead-pipe (uniform) or Cogwheel (ratchet-like); non-velocity        |
|               dependent; affects both flexors and extensors equally               |
+-----------------------------------------------------------------------------------+
| A - Akinesia / Bradykinesia: Slowness of execution, initiation hesitation, and    |
|                              progressive amplitude decay (hypokinesia)            |
+-----------------------------------------------------------------------------------+
| P - Postural Instability: Loss of postural righting reflexes; retropulsion;       |
|                           abnormal Backward Pull Test (≥3 steps or falling)       |
+-----------------------------------------------------------------------------------+

Clinical Distinction: Rigidity vs. Pyramidal Spasticity

A frequent DHA examination question tests the fundamental physiological distinction between basal ganglia rigidity and upper motor neuron (corticospinal) spasticity:

Manifestations of Bradykinesia and Akinesia

Bradykinesia is not merely sluggishness; it encompasses a pervasive degradation of motor sequencing:

• Hypokinesia / Micrographia: Progressive diminution in movement amplitude. In handwriting, letter size progressively shrinks across the page.
• Hypophonia & Monotonic Speech: Soft, quiet voice lacking normal inflection.
• Masked Facies (Hypomimia): Loss of facial expression with reduced blink frequency.
• Sequence Decomposition: Complex motor actions (such as rising from a chair or rolling in bed) are fragmented into isolated, sequential sub-movements with loss of automaticity.
• Gait Manifestations: Decreased or absent bilateral arm swing, reduced step height (shuffling), and flexed stooped posture.

Postural Instability & The Backward Pull Test

Postural instability is typically absent in early stages and emerges in Hoehn and Yahr Stage 3. It is evaluated clinically using the Backward Pull Test (Retropulsion Test):

• Execution: The examiner stands behind the patient, explains the procedure, and delivers a brisk, firm backward tug to the patient's shoulders.
• Normal Response: Recovers balance independently with 1 or 2 backward steps.
• Abnormal Response: Takes 3 or more retro-steps without balance recovery, or falls backward without stepping, requiring the examiner to physically catch them.

---

3. Hoehn and Yahr Clinical Staging

The Hoehn and Yahr (H&Y) scale is the globally accepted metric for tracking clinical progression and functional disability in Parkinson Disease:

[!IMPORTANT] The Critical H&Y Milestone: The transition from Stage 2 to Stage 3 is defined strictly by the emergence of postural instability (demonstrated by an abnormal pull test). Stage 2 patients have bilateral disease but normal balance reflexes. Once balance reflexes become impaired, the patient advances to Stage 3.

---

4. Freezing of Gait (FOG) & Motor Blockades

Freezing of Gait (FOG) is a debilitating episodic motor block characterized by a brief, sudden inability to initiate or continue forward stepping. Patients describe the sensation that their "feet are glued to the floor."

+-----------------------------------------------------------------------------------+
|                   Freezing of Gait (FOG) Triggers & Subtypes                      |
+-----------------------------------------------------------------------------------+
| 1. Start Hesitation: Inability to take the initial step when rising to walk       |
| 2. Turn Hesitation: Freezing triggered by turning around in a tight circle        |
| 3. Destination Hesitation: Freezing when approaching a chair or target destination|
| 4. Spatial / Threshold Freezing: Triggered by narrow doorways, elevators, crowds  |
| 5. Dual-Task Freezing: Triggered by simultaneous cognitive or motor demands       |
+-----------------------------------------------------------------------------------+

Pathophysiological Basis of Freezing

FOG is rooted in a functional breakdown between the frontal executive cortex, supplementary motor area (SMA), and the pedunculopontine nucleus (PPN) within the brainstem locomotor center. When spatial constraints (doorways) or directional changes (turns) require a rapid recalibration of step length and cadence, the striatum fails to generate the required motor program, producing high-frequency trembling of the knees (knee trembling at 3–8 Hz) without forward translation, precipitating severe falls.

---

5. External Sensory Cueing Strategies

External cueing is one of the most powerful, evidence-based physical therapy interventions for overcoming freezing of gait and hypokinesia in Parkinson Disease.

                       ┌─────────────────────────────────────┐
                       │ NORMAL AUTOMATIC BASAL GANGLIA LOOP │
                       │ (Basal Ganglia ──> SMA ──> Motor)   │
                       │       [ SEVERELY DEFICIENT IN PD ]  │
                       └──────────────────┬──────────────────┘
                                          │
                         ┌────────────────┴────────────────┐
                         │   EXTERNAL SENSORY CUE APPLIED  │
                         │   (Visual, Auditory, Conscious) │
                         └────────────────┬────────────────┘
                                          │
                                          ▼
               ┌─────────────────────────────────────────────────────┐
               │ ALTERNATIVE COMPENSATORY MOTOR CIRCUITS ACTIVATED   │
               │ - Premotor Cortex (Parieto-Frontal Pathway)         │
               │ - Cerebello-Thalamo-Cortical Pathways               │
               │ - Visual / Auditory Association Areas               │
               └──────────────────────────┬──────────────────────────┘
                                          │
                                          ▼
                        [ RESTORATION OF STRIDE LENGTH ]
                        [ BREAKDOWN OF FREEZING MOTOR BLOCK ]

The Three Primary Cueing Modalities

1. Visual Cues (Spatial Modality):

   • Mechanism: Visual targets activate the dorsal visual stream, parietal cortex, and lateral premotor cortex, entirely bypassing the dysfunctional basal ganglia-SMA loop.
   • Application: High-contrast transverse stripes (bright colored tape) placed on the floor perpendicular to the walking path, spaced exactly to the patient's target stride length. Laser light projections emitted from specialized canes or wheeled walkers that project a bright red horizontal line onto the floor directly in front of the patient.
   • Instruction: "Step completely over the line with your lead foot."

2. Auditory Cues (Temporal Modality):

   • Mechanism: Rhythmic acoustic stimuli engage the auditory-motor synchronization network via the vestibulocochlear nerve, reticulospinal tracts, and cerebellar circuits.
   • Application: Rhythmic Auditory Stimulation (RAS) using a wearable metronome or rhythmic music with a pronounced, predictable beat. The beat is typically set to the patient's baseline walking cadence or adjusted 10% faster to increase velocity, or 10% slower to encourage longer step lengths.
   • Instruction: "Match your heel strike exactly to the click of the beat."

3. Attentional / Cognitive Strategies (Cortical Volitional Modality):

   • Mechanism: Transforming an automatic, subcortical movement into a conscious, volitional motor act driven directly by the prefrontal cortex.
   • Application: Teaching the patient mental motor rehearsal and internal self-talk: "Think BIG steps," "Heel first," "Lift knees high."
   • Break-the-Freeze Technique: When frozen, the patient is taught to: Stop, Stand tall, Shift weight side-to-side, and then take a large lateral or backward step before resuming forward movement.

---

6. Evidence-Based Physical Therapy Interventions

Modern Parkinson neurorehabilitation rejects passive modalities in favor of intensive, active, high-effort exercise paradigms designed to stimulate neuroplasticity and dopaminergic receptor sensitivity.

The LSVT BIG Protocol

LSVT BIG (Lee Silverman Voice Treatment - Big) is an intensive, standardized physical therapy exercise program based on principles of motor learning and sensorimotor recalibration:

• Core Philosophy: Overcomes sensory under-scaling (patients with PD feel their small movements are normal sized) by forcing maximum movement amplitude across all functional motor tasks.
• Protocol Intensity: 16 individual 60-minute sessions delivered 4 consecutive days per week for 4 weeks, coupled with daily home exercise assignments.
• Effort Level: High cognitive and physical effort, targeting a perceived exertion of 8 out of 10 on a modified Borg scale.
• Key Components: Maximum amplitude sustained stretches, multi-directional functional stepping (backward, sideways, forward), dynamic rock-and-reach sequences, and personalized functional task practice (e.g., rising from a low chair, entering a car, buttoning a shirt).

Forced-Use Aerobic Exercise

Research demonstrates that high-intensity, forced-rate exercise stimulates brain-derived neurotrophic factor (BDNF) release and enhances corticomotor excitability:

• High-Cadence Cycling: Pedaling on a motorized or tandem stationary bicycle at a forced cadence of 80 to 90 revolutions per minute (rpm) (well beyond the patient's self-selected cadence of 50–60 rpm) for 30–45 minutes, 3 days per week. This produces significant, sustained reductions in tremor, bradykinesia, and UPDRS motor scores.
• Treadmill Training with Body-Weight Support: Enables high-volume repetitive stepping with rhythmic auditory pacing, improving gait symmetry and endurance.

Postural Extension and Agility Training

To combat the progressive forward-flexed posture (camptocormia) and axial rigidity:

• Extension & Rotation Exercises: Prone press-ups, quadruped bird-dog, thoracic extension over a foam roller, and seated or standing spinal axial rotation.
• Agility & Dual-Task Training: Tai Chi, non-contact boxing, dance (tango), and multi-directional obstacle courses that integrate cognitive tasks (e.g., naming words or counting backward by 7s while navigating obstacles).

---

7. Levodopa Pharmacokinetics & Therapy Synchronization

Pharmacological management in PD relies primarily on dopamine replacement therapy using Carbidopa/Levodopa (Sinemet). Understanding its pharmacokinetics is vital for clinical scheduling.

+-----------------------------------------------------------------------------------+
|                Levodopa Motor Fluctuations & Therapy Timing                       |
+-----------------------------------------------------------------------------------+
| DOSE ADMINISTERED ───> Rapid Absorption in Proximal Small Intestine               |
|                              │                                                    |
|                              ▼                                                    |
| 45 to 60 MINUTES POST-DOSE: 'ON' PERIOD (Peak Plasma Levodopa Concentration)      |
|   - Tremor, rigidity, and bradykinesia markedly suppressed                        |
|   - Optimal mobility, motor learning, and highest physical tolerance              |
|   - *** MANDATORY TIMING FOR ACTIVE PHYSICAL THERAPY SESSIONS ***                 |
|                              │                                                    |
|                              ▼                                                    |
| 2 to 3 HOURS POST-DOSE: POTENTIAL PEAK-DOSE DYSKINESIAS                           |
|   - Involuntary choreiform, dance-like, writhing movements of neck, trunk, limbs   |
|   - Caused by excessive striatal dopamine stimulation; adjust exercise intensity  |
|                              │                                                    |
|                              ▼                                                    |
| 3 to 4 HOURS POST-DOSE: 'WEARING-OFF' / 'OFF' PERIOD                              |
|   - Rapid return of severe bradykinesia, rigidity, tremor, and freezing           |
|   - High fall risk; reserve for assessing home rescue techniques and baseline risk|
+-----------------------------------------------------------------------------------+

[!TIP] Scheduling Rule for the Clinic: Standard physical therapy sessions targeting strengthening, balance, transfers, and gait training should always be scheduled 45 to 60 minutes after the morning dose of levodopa to coincide with the peak "ON" state. If a therapist needs to evaluate the patient's worst-case fall risk, freezing triggers, or the effectiveness of compensatory cueing under emergency conditions, a dedicated evaluation during the "OFF" phase may be conducted.